Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbiotic-GI-16: PF-08634404 with chemotherapy ± nivolumab in first-line advanced gastric or esophageal adenocarcinoma
jRCT2041260057Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of PF-08634404 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Pfizer. Primary endpoints: Confirmed objective response rate (ORR) by investigator - Phase 2, Number of participants with treatment-emergent adverse events - Phase 2 and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2041260057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260057.